Dendritic cells (DCs) are able to orchestrate innate and acquired immunity and can activate and sustain a long-lasting anti-tumor immune response in vivo when used as anti-tumor cell therapy. The selection of the antigen and the choice of its formulation are key points in designing anti-cancer DC-based vaccines. Cell released vesicles/exosomes have been shown to transfer antigens, HLAI/peptide complexes and co-stimulatory molecules to recipient cells. In this study we describe the generation of an allogenic microvesicle cell factory in which the expression of a specific tumor antigen was combined to the expression of co-stimulatory and allogeneic molecules. The DG75 lymphoblastoid cell line was selected as microvesicle producer and transfected with ErbB2, as tumor antigen prototype. The shed microvesicles transferred antigenic components to recipient DCs, increasing their immunogenicity. DC pulsing resulted in cross-presentation of ErbB2 both in HLAI and HLAII compartments, and ErbB2-specific CD8(+) T cells from cancer patients were activated by DCs pulsed with vesicle-bound ErbB2. The microvesicle cell factory proposed may represent a source of cell free immunogen to be used for DC-based cancer therapy.

IMMUNOGENICITY OF ALLO-VESICLE CARRYING ERBB2 TUMOR ANTIGEN FOR DENDRITIC CELL-BASED ANTI-TUMOR IMMUNOTHERAPY / Napoletano, Chiara; Rughetti, Aurelia; R., Landi; D., Pinto; Bellati, Filippo; RAHIMI KOSHKAKI, Hassan; Spinelli, GIAN PAOLO; S., Pauselli; Sale, Patrizio; V., Dolo; F., De Lorenzo; Tomao, Federica; BENEDETTI PANICI, Pierluigi; Frati, Luigi; Nuti, Marianna. - In: INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY. - ISSN 0394-6320. - STAMPA. - 22:3(2009), pp. 647-658.

IMMUNOGENICITY OF ALLO-VESICLE CARRYING ERBB2 TUMOR ANTIGEN FOR DENDRITIC CELL-BASED ANTI-TUMOR IMMUNOTHERAPY

NAPOLETANO, Chiara;RUGHETTI, Aurelia;BELLATI, FILIPPO;RAHIMI KOSHKAKI, HASSAN;SPINELLI, GIAN PAOLO;SALE, PATRIZIO;F. De Lorenzo;TOMAO, FEDERICA;BENEDETTI PANICI, PIERLUIGI;FRATI, Luigi;NUTI, Marianna
2009

Abstract

Dendritic cells (DCs) are able to orchestrate innate and acquired immunity and can activate and sustain a long-lasting anti-tumor immune response in vivo when used as anti-tumor cell therapy. The selection of the antigen and the choice of its formulation are key points in designing anti-cancer DC-based vaccines. Cell released vesicles/exosomes have been shown to transfer antigens, HLAI/peptide complexes and co-stimulatory molecules to recipient cells. In this study we describe the generation of an allogenic microvesicle cell factory in which the expression of a specific tumor antigen was combined to the expression of co-stimulatory and allogeneic molecules. The DG75 lymphoblastoid cell line was selected as microvesicle producer and transfected with ErbB2, as tumor antigen prototype. The shed microvesicles transferred antigenic components to recipient DCs, increasing their immunogenicity. DC pulsing resulted in cross-presentation of ErbB2 both in HLAI and HLAII compartments, and ErbB2-specific CD8(+) T cells from cancer patients were activated by DCs pulsed with vesicle-bound ErbB2. The microvesicle cell factory proposed may represent a source of cell free immunogen to be used for DC-based cancer therapy.
2009
anti-tumor immune response; antigen presentation; cancer immunotherapy; cancer vaccine; dendritic cells; erbb2; microvesicle
01 Pubblicazione su rivista::01a Articolo in rivista
IMMUNOGENICITY OF ALLO-VESICLE CARRYING ERBB2 TUMOR ANTIGEN FOR DENDRITIC CELL-BASED ANTI-TUMOR IMMUNOTHERAPY / Napoletano, Chiara; Rughetti, Aurelia; R., Landi; D., Pinto; Bellati, Filippo; RAHIMI KOSHKAKI, Hassan; Spinelli, GIAN PAOLO; S., Pauselli; Sale, Patrizio; V., Dolo; F., De Lorenzo; Tomao, Federica; BENEDETTI PANICI, Pierluigi; Frati, Luigi; Nuti, Marianna. - In: INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY. - ISSN 0394-6320. - STAMPA. - 22:3(2009), pp. 647-658.
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/359104
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 28
social impact